Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2019 3
2020 4
2021 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

9 results

Results by year

Filters applied: . Clear all
Page 1
Administration of subcutaneous interferon beta 1a in the evening: data from RELIEF study.
Patti F, Zimatore GB, Brescia Morra V, Aguglia U, Bossio RB, Marziolo R, Valentino P, Chisari CG, Capacchione A, Zappia M; RELIEF Study Group. Patti F, et al. Among authors: capacchione a. J Neurol. 2020 Jun;267(6):1812-1823. doi: 10.1007/s00415-020-09771-x. Epub 2020 Mar 5. J Neurol. 2020. PMID: 32140867 Clinical Trial.
Coenzyme Q10 supplementation reduces peripheral oxidative stress and inflammation in interferon-β1a-treated multiple sclerosis.
Moccia M, Capacchione A, Lanzillo R, Carbone F, Micillo T, Perna F, De Rosa A, Carotenuto A, Albero R, Matarese G, Palladino R, Brescia Morra V. Moccia M, et al. Among authors: capacchione a. Ther Adv Neurol Disord. 2019 Feb 18;12:1756286418819074. doi: 10.1177/1756286418819074. eCollection 2019. Ther Adv Neurol Disord. 2019. PMID: 30815035 Free PMC article.
ProspeCtive study to evaluate efficacy, safety and tOlerability of dietary supplemeNT of Curcumin (BCM95) in subjects with Active relapsing MultIple Sclerosis treated with subcutaNeous Interferon beta 1a 44 mcg TIW (CONTAIN): A randomized, controlled trial.
Petracca M, Quarantelli M, Moccia M, Vacca G, Satelliti B, D'Ambrosio G, Carotenuto A, Ragucci M, Assogna F, Capacchione A, Lanzillo R, Morra VB. Petracca M, et al. Among authors: capacchione a. Mult Scler Relat Disord. 2021 Nov;56:103274. doi: 10.1016/j.msard.2021.103274. Epub 2021 Sep 21. Mult Scler Relat Disord. 2021. PMID: 34583214 Clinical Trial.
Healthcare resource utilization and costs for multiple sclerosis management in the Campania region of Italy: Comparison between centre-based and local service healthcare delivery.
Moccia M, Tajani A, Acampora R, Signoriello E, Corbisiero G, Vercellone A, Sergianni P, Pennino F, Lanzillo R, Palladino R, Capacchione A, Brescia Morra V, Lus G, Triassi M. Moccia M, et al. Among authors: capacchione a. PLoS One. 2019 Sep 19;14(9):e0222012. doi: 10.1371/journal.pone.0222012. eCollection 2019. PLoS One. 2019. PMID: 31536513 Free PMC article.
Persistence, adherence, healthcare resource utilisation and costs for interferon Beta in multiple sclerosis: a population-based study in the Campania region (southern Italy).
Moccia M, Loperto I, Lanzillo R, Capacchione A, Carotenuto A, Triassi M, Brescia Morra V, Palladino R. Moccia M, et al. Among authors: capacchione a. BMC Health Serv Res. 2020 Aug 26;20(1):797. doi: 10.1186/s12913-020-05664-x. BMC Health Serv Res. 2020. PMID: 32847587 Free PMC article.